Journal of Liver Cancer最新文献_第7页

Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report. 使用 nivolumab 完全治愈伴有多处肺转移的浸润性肝细胞癌：病例报告。

Journal of Liver Cancer Pub Date : 2021-09-01 Epub Date: 2021-09-30 DOI: 10.17998/jlc.2021.08.26

Ji Eun Han, Hyo Jung Cho, Soon Sun Kim, Jae Youn Cheong

{"title":"Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report.","authors":"Ji Eun Han, Hyo Jung Cho, Soon Sun Kim, Jae Youn Cheong","doi":"10.17998/jlc.2021.08.26","DOIUrl":"10.17998/jlc.2021.08.26","url":null,"abstract":"The current Food and Drug Administration-approved systemic treatments for advanced hepatocellular carcinoma (HCC) include multikinase inhibitors (tyrosine kinase inhibitor [TKI]) and immune checkpoint inhibitors (ICIs). Among ICIs, nivolumab is used as second-line therapy for advanced HCC after sorafenib failure or patient intolerance. In this case, a patient with infiltrative HCC and portal vein tumor thrombosis was treated with hepatic arterial infusion chemotherapy (HAIC) and radiation therapy. New lung metastasis developed after HAICs; thus, lenvatinib treatment was initiated. However, the disease progressed. Thereafter, sorafenib treatment was initiated but he developed intolerance, with grade 3 sorafenib-related diarrhea. Subsequently, nivolumab was administered as rescue therapy. He demonstrated a partial response to nivolumab after the third treatment and viable HCCs in the lungs and liver completely disappeared after the 24th treatment. These findings suggest that nivolumab could be used as an effective rescue therapy for advanced HCC progression after TKI treatment.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"21 2","pages":"169-176"},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7e/df/jlc-2021-08-26.PMC10035689.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9791905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis. 肝细胞癌合并门静脉肿瘤血栓的肝移植治疗。

Journal of Liver Cancer Pub Date : 2021-09-01 DOI: 10.17998/jlc.2021.03.17

Sang Jin Kim, Jong Man Kim

{"title":"Liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis.","authors":"Sang Jin Kim, Jong Man Kim","doi":"10.17998/jlc.2021.03.17","DOIUrl":"https://doi.org/10.17998/jlc.2021.03.17","url":null,"abstract":"Traditionally, liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis is not recommended. However, with recent developments in locoregional therapies for hepatocellular carcinoma, more aggressive treatments have been attempted for advanced hepatocellular carcinoma. Recently, various studies on locoregional therapies for downstaging followed by living donor liver transplantation reported inspiring overall survival and recurrence-free survival of patients. These downstaging procedures included three-dimensional conformal radiation therapy, trans-arterial chemoembolization, stereotactic body radiation therapy, trans-arterial radioembolization, hepatic arterial infusion chemotherapy and combinations of these therapies. Selection of the optimal downstaging protocol should depend on tumor location, biology and background liver status. The risk factors affecting outcome include pre-downstaging alpha-fetoprotein values, delta alpha-fetoprotein values, disappearance of portal vein tumor thrombosis on imaging and meeting the Milan criteria or not after downstaging. For hepatocellular carcinoma with portal vein tumor thrombosis, downstaging procedure with liver transplantation in mind would be helpful. If the reaction of the downstaged tumor is good, liver transplantation may be performed.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"21 2","pages":"105-112"},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/23/a5/jlc-2021-03-17.PMC10035684.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9739393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment. 晚期肝癌的全身治疗:二线治疗选择的考虑。

Journal of Liver Cancer Pub Date : 2021-09-01 DOI: 10.17998/jlc.2021.09.23

Bo Hyun Kim, Joong-Won Park

引用次数: 2

Curative liver transplantation after lung resection for advanced hepatocellular carcinoma with lung metastasis and inferior vena cava tumor thrombosis: a case report. 晚期肝癌伴肺转移及下腔静脉肿瘤血栓形成肺切除术后肝移植的疗效报告1例。

Journal of Liver Cancer Pub Date : 2021-09-01 DOI: 10.17998/jlc.2021.09.08

Dong Jin Joo, Do Young Kim, Jinsil Seong, Hyun Jeong Kim, Jae Geun Lee, Dai Hoon Han, Gi Hong Choi, Myoung Soo Kim, Jin Sub Choi, Soon Il Kim

引用次数: 1

The effect of nucleos(t)ide analogues on clinical outcomes of patients treated with transarterial chemoembolization and radiofrequency ablation for hepatitis B virus-related hepatocellular carcinoma. 核苷类似物对经动脉化疗栓塞和射频消融治疗乙型肝炎病毒相关肝细胞癌患者临床结局的影响

Journal of Liver Cancer Pub Date : 2021-09-01 DOI: 10.17998/jlc.2021.09.22

Jae Min Park, Won Hyeok Choe, Jeong Han Kim, So Young Kwon, Byung Chul Yoo

{"title":"The effect of nucleos(t)ide analogues on clinical outcomes of patients treated with transarterial chemoembolization and radiofrequency ablation for hepatitis B virus-related hepatocellular carcinoma.","authors":"Jae Min Park, Won Hyeok Choe, Jeong Han Kim, So Young Kwon, Byung Chul Yoo","doi":"10.17998/jlc.2021.09.22","DOIUrl":"https://doi.org/10.17998/jlc.2021.09.22","url":null,"abstract":"Background/aims: Because hepatitis B virus (HBV) replication has been known to play an important role in cancer recurrence after curative treatment of HBV-related hepatocellular carcinoma (HCC), we examined whether treatment based on nucleos(t)ide analogues (NAs) might decrease the recurrence rate and improve patient survival.Methods: The retrospective cohort study enrolled 73 patients with chronic hepatitis B who were treated with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) with curative intent for HCC. Among those, 30 and 43 patients were treated with tenofovir disoproxil fumarate (TDF) and entecavir (ETV), respectively.Results: Of the 73 patients, 51 experienced HCC recurrence, and 14 patients were dead during a follow-up of 73±34 months. Multivariate analyses showed that tumor size (hazard ratio [HR], 1.590; 95% confidence-interval [CI], 1.106-2.285; P=0.012) and Child-Pugh class B (vs. class A/non cirrhosis; HR, 5.794; 95% CI, 2.311-14.523; P=0.001) was significantly associated with HCC recurrence, and Child-Pugh class B (HR, 7.357; 95% CI, 2.100-25.777; P=0.002) was an independent unfavorable prognostic factor for survival. During NAs therapy, TDF was superior to ETV for complete viral response at 1 year after the date of combination of TACE and RFA (P=0.016). However, the risks of HCC recurrence and survival were not significantly different between those treated with TDF versus ETV.Conclusions: TDF was superior to ETV for achieving complete viral response. However, the recurrence and mortality after TACE and RFA for HBV-related HCC were not significantly different between patients treated with TDF versus ETV.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"21 2","pages":"155-162"},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2d/37/jlc-2021-09-22.PMC10035688.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9736714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Complete response in hepatocellular carcinoma with lymph node metastasis by combination therapy of atezolizumab and bevacizumab: a case report. 阿特唑单抗和贝伐单抗联合治疗肝细胞癌伴淋巴结转移的完全缓解:1例报告。

Journal of Liver Cancer Pub Date : 2021-09-01 DOI: 10.17998/jlc.2021.09.10

Sang Youn Hwang, Sun Mi Lee, Jeong Woo Lim, Gi Jung Jeon, Hye Won Lee

引用次数: 0

Long-term survival after multimodal treatment involving radiotherapy for huge hepatocellular carcinoma with oligometastasis: a case report. 多模式治疗合并放射治疗巨大肝癌伴少转移的长期生存:1例报告。

Journal of Liver Cancer Pub Date : 2021-09-01 DOI: 10.17998/jlc.2021.08.06

Byung Min Lee, Jinsil Seong

引用次数: 0

A Case of Lymphocyte-Rich Hepatocellular Carcinoma in a Patient Who Was Treated for Colon Cancer. 一例曾接受结肠癌治疗的患者体内富含淋巴细胞的肝细胞癌。

Journal of Liver Cancer Pub Date : 2021-03-01 Epub Date: 2021-03-31 DOI: 10.17998/jlc.21.1.69

Jae Won Song, Ho Soo Chun, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Young Nyun Park, Dai Hoon Han, Do Young Kim

引用次数: 0

Prediction of Post-resection Prognosis Using the ADV Score for Huge Hepatocellular Carcinomas ≥13 cm. ≥13 cm巨大肝细胞癌ADV评分预测术后预后

Journal of Liver Cancer Pub Date : 2021-03-01 DOI: 10.17998/jlc.21.1.45

Shin Hwang, Ki-Hun Kim, Deok-Bog Moon, Chul-Soo Ahn, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park

{"title":"Prediction of Post-resection Prognosis Using the ADV Score for Huge Hepatocellular Carcinomas ≥13 cm.","authors":"Shin Hwang, Ki-Hun Kim, Deok-Bog Moon, Chul-Soo Ahn, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park","doi":"10.17998/jlc.21.1.45","DOIUrl":"https://doi.org/10.17998/jlc.21.1.45","url":null,"abstract":"Background/aims: Multiplication of α-fetoprotein, des-γ-carboxy prothrombin, and tumor volume (ADV score) is a surrogate marker for post-resection prognosis of hepatocellular carcinoma (HCC). This study aimed to validate the predictive power of the ADV score-based prognostic prediction model for patients with solitary huge HCC.Methods: Of 3,018 patients, 100 patients who underwent hepatic resection for solitary HCC ≥13 cm between 2008 and 2012 were selected.Results: The median tumor diameter and tumor volume were 15.0 cm and 886 mL, respectively. Tumor recurrence and overall survival (OS) rates were 70.7% and 66.0% at one year and 84.9% and 34.0% at five years, respectively. Microvascular invasion (MVI) was the only independent risk factor for disease-free survival (DFS) and OS. DFS and OS, stratified by ADV score with 1-log intervals, showed significant prognostic contrasts (P=0.007 and P=0.017, respectively). DFS and OS, stratified by ADV score with a cut-off of 8-log, showed significant prognostic contrasts (P=0.014 and P=0.042, respectively). The combination of MVI and ADV score with a cut-off of 8-log also showed significant prognostic contrasts in DFS (P<0.001) and OS (P=0.001) considering the number of risk factors. Prognostic contrast was enhanced after combining the MVI and ADV score.Conclusions: The prognostic prediction model with the ADV score could reliably predict the risk of tumor recurrence and long-term patient survival outcomes in patients with solitary huge HCC ≥13 cm. The results of this study suggest that our prognostic prediction models can be used to guide surgical treatment and post-resection follow-up for patients with huge HCCs.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"21 1","pages":"45-57"},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1a/4b/jlc-21-1-45.PMC10035719.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9736407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rare Case of Pyogenic Brain Abscess after Transarterial Chemoembolization in a Patient with Hepatocellular Carcinoma: Case Report and Literature Review. 肝细胞癌患者经动脉化疗栓塞术后出现化脓性脑脓肿的罕见病例：病例报告和文献综述。

Journal of Liver Cancer Pub Date : 2021-03-01 Epub Date: 2021-03-31 DOI: 10.17998/jlc.21.1.81

Jun-Ho Myeong, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim

引用次数: 0